4.8 Letter

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

Journal

NEW ENGLAND JOURNAL OF MEDICINE
Volume 384, Issue 1, Pages 80-+

Publisher

MASSACHUSETTS MEDICAL SOC
DOI: 10.1056/NEJMc2032195

Keywords

-

Funding

  1. National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) [UM1AI148373, UM1AI148576, UM1AI148684, NIH P51 OD011132, NIH AID AI149644, UM1Al148684-01S1, HHSN272201500002C]
  2. National Center for Advancing Translational Sciences, NIH [UL1 TR002243]
  3. Dolly Parton Covid-19 Research Fund
  4. Emory Executive Vice President for Health Affairs Synergy Fund award
  5. Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta
  6. Covid-Catalyst-I3 Fund from the Woodruff Health Sciences Center
  7. Covid-Catalyst-I3 Fund from the Emory School of Medicine
  8. North Carolina Policy Collaboratory at the University of North Carolina at Chapel Hill
  9. North Carolina Coronavirus Relief Fund
  10. Intramural Research Program of the Vaccine Research Center, NIAID, NIH
  11. Coalition for Epidemic Preparedness Innovation

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available